Compare Medpace Holdings Inc (MEDP) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Schwab US Dividend Equity ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Schwab US Dividend Equity ETF trades at $33.04 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is far larger — about 6.6× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Schwab US Dividend Equity ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| MEDP | SCHD | |
|---|---|---|
Market Cap | $16.82B | $110.56B |
Volume | 223,093 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $630.19 | $35.21 |
52-Week Low | $393.42 | $26.44 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
SCHD trades at $33.04, up 1.19% today, with a bullish technical signal but mixed moving averages. The ETF focuses on high-quality U.S. dividend stocks, though key valuation ratios like P/E and P/B are not provided in the data. Recent news highlights its outperformance versus the S&P 500 in 2026 and a dividend payment scheduled for September 28, 2026.
Outlook is supported by dividend growth and defensive positioning, but risks include interest rate sensitivity and strict selection rules that may exclude high-growth stocks. Analyst sentiment is mixed, with technical indicators suggesting near-term consolidation around key support at $33.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
